利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

395 条记录 (耗时 0.034 秒)

    Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
    3.
    发明公开
    Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression 审中-公开
    镇静剂的组合和用于改善睡眠和抑郁症治疗的质量的神经递质调制器和方法

    公开(公告)号：EP2343073A2

    公开(公告)日：2011-07-13

    申请号：EP11158892.7

    申请日：2004-12-08

    申请人： Sepracor Inc.

    发明人： Lalji, Karim ,  Barberich, Timothy, J ,  Caron, Judy ,  Wessel, Thomas

    IPC分类号： A61K31/4985 ,  A61K31/138 ,  A61P25/20 ,  A61P25/24

    CPC分类号： A61K31/4985 ,  A61K31/137 ,  A61K31/138 ,  A61K31/495 ,  A61K31/724 ,  A61K45/06 ,  A61K2300/00

    摘要： One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and/or depression. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 5-HT 2A modulator, or dopamine reuptake inhibitor. In certain embodiments, the pharmaceutical composition comprises eszopiclone. In a preferred embodiment, the pharmaceutical composition comprises eszopiclone and fluoxetine. The present invention also relates to a method of treating a sleep abnormality, treating insomnia, treating depression, augmenting antidepressant therapy, eliciting a dose-sparing effect, reducing depression relapse, improving the efficacy of antidepressant therapy or improving the tolerability of antidepressant therapy, comprising co-administering to a patient in need thereof a GABA-receptor-modulating compound; and a SRI, NRI, 5-HT2 A modulator or DRI.

    摘要翻译： 本发明的一个方面涉及含有两种或多种活性剂的药物组合物做了当一起可用于治疗，E. G.，失眠和/或抑郁症。 所述药物组合物的第一组分是GABA受体调节化合物。 所述药物组合物的第二组分是血清素再摄取抑制剂，去甲肾上腺素再摄取抑制剂，5-HT 2A调节剂或多巴胺再摄取抑制剂。 在某些实施方案中，药物组合物包含艾司佐匹克隆。 在优选实施方案中，所述药物组合物包含艾司佐匹克隆和氟西汀。 因此，本发明涉及治疗睡眠异常，治疗失眠，治疗抑郁症，增强抗抑郁药治疗，引发剂量节约效应，减少抑郁复发，改善抗抑郁药治疗的功效或改进抗抑郁药治疗的方法，包括耐受性的方法 共同给予需要它们的GABA受体的调节性化合物的患者; 和SRI，NRI，5-HT2的调制器或DRI。

    SOLID FORMS COMPRISING (-) O-DESMETHYLVENLAFAXINE AND USES THEREOF
    7.
    发明公开
    SOLID FORMS COMPRISING (-) O-DESMETHYLVENLAFAXINE AND USES THEREOF 有权
    FESTE FORMEN MIT（ - ） - O-DESMETHYLVENLAFAXIN UND VERWENDUNGEN DAVON

    公开(公告)号：EP2114863A2

    公开(公告)日：2009-11-11

    申请号：EP08725968.5

    申请日：2008-02-21

    申请人： Sepracor Inc.

    发明人： SIZENSKY, Michael ,  WILKINSON, Harold, S. ,  SNOONIAN, John ,  KIM, Norman ,  LAUGHLIN, Sharon, M. ,  BAKALE, Roger, P. ,  PLUNKETT, Kevin ,  MOUSAW, Patrick

    IPC分类号： C07C215/64 ,  A61K31/137 ,  A61P25/00

    CPC分类号： C07C215/64 ,  C07B2200/07 ,  C07B2200/13 ,  C07C213/10 ,  C07C2601/14

    摘要： Solid forms comprising a compound useful in the treatment, prevention and management of various conditions and diseases are provided herein. In particular, the invention provides solid forms comprising (-)-O-desmethylvenlafaxine, including salts thereof, having utility for the treatment, prevention and management of conditions and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.

    摘要翻译： 本文提供了包含可用于治疗，预防和治疗各种病症和疾病的化合物的固体形式。 特别地，本发明提供了包含（ - ） - O-去甲基文拉法辛（包括其盐）的固体形式，其可用于治疗，预防和治疗病症和病症，包括但不限于情感障碍如抑郁症，双相和躁狂症 失调，注意力缺陷障碍，多动症的注意力缺陷障碍，帕金森病，癫痫，脑功能障碍，肥胖和体重增加，失禁，痴呆和相关疾病。